Kiora, Théa to Develop, Commercialize Treatment of Inherited Retinal Diseases; Deal Value up to $301 M

  Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), a clinical-stage biotech company developing treatments for orphan retinal diseases, today announced that it has entered a strategic development and commercialization agreement with Théa Open Innovation (TOI), a sister company of the global ophthalmic specialty company Laboratoires Théa (Théa). Under the agreement, Kiora granted TOI exclusive worldwide development and commercialization rights, excluding Asia, to KIO-301 for the treatment of degenerative retinal diseases. In exchange, Kiora will receive an upfront, payment of $16 million; up to $285 million upon achievement of pre-specified clinical development, regulatory and commercial milestones; tiered royalties of up to low 20% on net sales; and reimbursement of KIO-301 research and development expenses.

https://www.newsfilecorp.com/release/196399/Kiora-Pharmaceuticals-and-Tha-Open-Innovation-Enter-Strategic-Agreement-to-Develop-and-Commercialize-KIO301-for-the-Treatment-of-Inherited-Retinal-Diseases-Total-Deal-Value-of-up-to-301-Million-includes-16-Million-Upfront-up-to-285-Million-